BL Pharmtech

At a glance

BL Pharmtech filed 23 disclosures in the last 12 months, including 2 insider and 2 5% holder. The most recent key filing was on Mar 23.

Revenue for 2025 was ₩6.5B, down 26.1% on 2024. It made an operating loss of ₩2.8B. Debt was 130% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩1.4B and operating loss of ₩1.3B.

The 2025 annual report lists 10 employees with an average tenure of 6.2 years and average pay of ₩37.5M. Its 5 directors and auditors were paid ₩5M each on average. It paid no cash dividend for 2025. 박영철 and related parties held 27.52% at year end.

From the 2025 annual report

Staff: 10 (5 men, 5 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩426M. Directors and auditors: 5, paid ₩24M in total.

No cash dividend was paid for 2025.

Largest shareholder

박영철 holds 25.30%; with 4 related parties the group holds 27.52% of common shares at year end.

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary